Pharmacokinetic Study of Adjuvant Gemcitabine Therapy for Biliary Tract Cancer following Major Hepatectomy (KHBO1101)

BACKGROUND: Biliary tract cancer (BTC) patients who have undergone surgical resection with major hepatectomy cannot tolerate the standard gemcitabine regimen (1,000 mg/m(2) on days 1, 8, and 15 every 4 weeks) due to severe toxicities such as myelosuppression. Our dose-finding study of adjuvant gemci...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujiwara, Yutaka, Kobayashi, Shogo, Nagano, Hiroaki, Kanai, Masashi, Hatano, Etsuo, Toyoda, Masanori, Ajiki, Tetsuo, Takashima, Yuki, Yoshimura, Kenichi, Hamada, Akinobu, Minami, Hironobu, Ioka, Tatsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669083/
https://www.ncbi.nlm.nih.gov/pubmed/26633034
http://dx.doi.org/10.1371/journal.pone.0143072

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669083/
https://www.ncbi.nlm.nih.gov/pubmed/26633034
http://dx.doi.org/10.1371/journal.pone.0143072

Ejemplares similares